LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.ESMO Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。 | PMID 41401771PMC12767809 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States.J Viral Hepat入排复审未纳入:The study is a Phase III randomized trial in an oncology-related field (hepatocellular carcinoma is listed as an outcome), but it is a health-economic modeling study evaluating a screening/testing strategy (double reflex testing) and linkage to care, not a trial of a drug intervention. It reports simulated outcomes (difference in event numbers) over a 5-year horizon from a payer perspective, not a primary time-to-event efficacy endpoint (e.g., OS, PFS) with KM/HR analysis for a drug. Therefore, it lacks the required drug intervention and primary time-to-event efficacy endpoint. | PMID 41405233PMC12710454 | 2026-Jan | 0.85 | The study is a Phase III randomized trial in an oncology-related field (hepatocellular carcinoma is listed as an outcome), but it is a health-economic modeling study evaluating a screening/testing strategy (double reflex testing) and linkage to care, not a trial of a drug intervention. It reports simulated outcomes (difference in event numbers) over a 5-year horizon from a payer perspective, not a primary time-to-event efficacy endpoint (e.g., OS, PFS) with KM/HR analysis for a drug. Therefore, it lacks the required drug intervention and primary time-to-event efficacy endpoint. | 无 KM 图 |
| Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases.EBioMedicineAI 判定该论文不进入自动 KM 提取:The study is an exploratory analysis of biomarkers within a phase-III trial but does not report the results of the phase-III randomized controlled clinical trial itself. | PMID 41406506PMC12768872 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41421034无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prediction of time to insulin initiation in gestational diabetes mellitus: a secondary analysis of the EMERGE trial.Diabetes Res Clin Pract疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41435972无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41449142无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41449145无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41449147无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41449150无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.Jpn J Ophthalmol已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图。 | PMID 41452565PMC12948824 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.Jpn J Ophthalmol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图。 | PMID 41452566PMC12948817 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.Nat CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41482527无 PMCID | 2026-Jan | 0.45 | The record describes a Phase III randomized trial in oncology with a drug intervention. However, the abstract does not explicitly report any primary or key secondary time-to-event efficacy results (e.g., overall survival, progression-free survival, hazard ratios, Kaplan-Meier curves, or specific outcome data). It focuses on biomarker and resistance mechanism analysis within the trial. Therefore, eligibility cannot be confirmed based on the provided metadata. | 无 KM 图 |
| The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 14 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 9 张未列出。 | PMID 41491103PMC12823442 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41494216无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia.J Clin Pharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41496255PMC12775547 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nat Cancer | PMID 41507539PMC12858404 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.Nat Cancer | PMID 41514054PMC12858396 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.Curr Med Res OpinPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41686056无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.Acta Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1.:非 KM 图;Fig. 2.:非 KM 图;Fig. 3.:非 KM 图;Fig. 4.:森林图/亚组分析图。 | PMID 40652928PMC12503453 | 2026 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial.Ann Nutr Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 flow diagram;Fig. 2.:AI 判定为 flow diagram;Fig. 3.:AI 判定为 other。 | PMID 40906605PMC12503829 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.CA Cancer J Clin | PMID 41287969PMC12645347 | 2026 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.Ann Hepatol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41453647无 PMCID | 2026 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.Asia Pac J Ophthalmol (Phila)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41519383无 PMCID | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.Helicobacter已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:研究设计图。 | PMID 41531249PMC12800724 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-Reported Outcomes after Surgery for Proliferative Vitreoretinopathy: Post hoc Analysis of a Randomized Controlled Trial.Ophthalmologica已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:生活质量量表图;Fig. 2.:生活质量量表图。 | PMID 41610080PMC12981897 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.Cancer Commun (Lond) | PMID 41625476PMC12857758 | 2026 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial.Drug Des Devel Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。 | PMID 41778148PMC12951296 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis.DermatitisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40152029无 PMCID | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis.Dermatitis入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41189512无 PMCID | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.CA Cancer J Clin疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:森林图/亚组分析图;FIGURE 3:瀑布图。 | PMID 41818162PMC12981368 | 2026 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial.PLoS One入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41779821PMC12959675 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.Cancer Commun (Lond) | PMID 41821581PMC12976379 | 2026 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis.J Clin DensitomPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41812602无 PMCID | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.PLoS One疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:森林图/亚组分析图;Fig 3:森林图/亚组分析图;Fig 4:森林图/亚组分析图。 | PMID 41990093PMC13086435 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology.Ophthalmol GlaucomaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41461224PMC13003422 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).Pediatr Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41795905PMC13206189 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.Front Immunol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。 | PMID 42164489PMC13183516 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.Drug Des Devel Ther已检查 6 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。 | PMID 42163997PMC13186222 | 2026 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 无 KM 图 |
| Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.Drug Des Devel Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:研究设计图;Figure 2:CONSORT/入组流程图;Figure 3:非 KM 图;Figure 4:AI 判定为 other;另有 2 张未列出。 | PMID 42199811PMC13199865 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.Front Immunol已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:CONSORT/入组流程图;Figure 3:CONSORT/入组流程图;Figure 4:CONSORT/入组流程图;Figure 5:CONSORT/入组流程图;另有 1 张未列出。 | PMID 42292352PMC13260720 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial.Drug Des Devel Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图。 | PMID 42266513PMC13245468 | 2026 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 无 KM 图 |
| SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.Front Immunol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 42344898PMC13286926 | 2026 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.Cancer Commun (Lond) | PMID 42282892PMC13250280 | 2026 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial.Front Immunol已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 42416060PMC13337383 | 2026 | 0.45 | The study is a randomized Phase III trial of a drug (adalimumab or its biosimilar) in humans with a malignant-neoplasm-adjacent mesh term (Spondylitis, Ankylosing) but is not an oncology study. It also does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 无 KM 图 |
| Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.Cancer Commun (Lond)入排复审未纳入:Randomized phase III breast cancer trial of a drug intervention, but its primary efficacy endpoint is ORR rather than a required time-to-event endpoint; thus it does not meet the cohort's time-to-event criterion. | PMID 42368972PMC13305025 | 2026 | 0.98 | Randomized phase III breast cancer trial of a drug intervention, but its primary efficacy endpoint is ORR rather than a required time-to-event endpoint; thus it does not meet the cohort's time-to-event criterion. | 无 KM 图 |
| A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.BMC Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:CONSORT/入组流程图;Fig. 3:ROC 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。 | PMID 41466188PMC12751179 | 2025-Dec-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial.BMC Musculoskelet Disord入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41466394PMC12859901 | 2025-Dec-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.Oncologist | PMID 41397917PMC12795601 | 2025-Dec-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen.Medicine (Baltimore)已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。 | PMID 41466018PMC12746988 | 2025-Dec-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials.BMJ Open入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41448717PMC12746493 | 2025-Dec-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |